US Eyes Label Changes for Testosterone Therapy as New Safety Data Emerge
US health officials are seeking label updates for testosterone replacement therapies after reviewing new safety data; although large studies found no meaningful rise in heart attacks or strokes among users, the proposed revisions would remove a blanket claim that safety and effectiveness aren’t established for age-related low testosterone and would update prostate cancer and enlarged-prostate warnings, with continued emphasis on proper diagnosis and ongoing monitoring; experts say the changes reflect evolving science and could improve access, but testosterone remains a medical therapy that should be prescribed only after thorough evaluation and not used indiscriminately; typical low testosterone is below about 300 ng/dL, though normal ranges vary by lab and guidelines.